Abstract：
We have conducted a retrospective, single-centre analysis of 20 patients with relapsed or refractory FLT3-mutated acute myeloid leukaemia (FLT3m AML) who received a salvage quadruplet regimen consisting of gilteritinib, venetoclax, low-dose cytarabine and actinomycin D (G-ACTIVE). G-ACTIVE resulted in a 95% (19/20) overall response rate and 75% (15/20) complete remission and complete remission with an incomplete platelet recovery (CR + CRp) rate. Out of 13 transplant-eligible patients, 11 (86%) proceeded to an allogeneic stem cell transplantation. The median overall survival and relapse-free survival after G-ACTIVE were 32 and 12.9 months respectively. The Day 60 mortality rate was 15%.
摘要：
我们进行了一次回顾,单中心分析20例复发性或难治性FLT3突变型急性髓系白血病（FLT3mAML）患者接受由gilteritinib组成的抢救四联疗法，维尼托克,低剂量阿糖胞苷和放线菌素D（G-ACTIVE）。G-ACTIVE导致95％（19/20）的总体反应率和75％（15/20）的完全缓解和完全缓解，血小板恢复不完全（CRCRp）率。在13名符合移植资格的患者中，11（86％）进行了异基因干细胞移植。G-ACTIVE后中位总生存期和无复发生存期分别为32个月和12.9个月。第60天死亡率为15%。
